HBW Insight editors discuss the latest European consumer healthcare industry news. This week, Tom Gallen and David Ridley look at the Q1 financial results of four major Europe-based OTC players - GSK, Sanofi, Bayer and Reckitt - to analyse the impact that the coronavirus is still having on the region's consumer healthcare industry. An almost non-existent cough and cold season, due to lockdown measures, and last year's stockpiling of OTC drugs, have led to double-digit decreases in Q1 sales. A continuing trend for wellness and dietary supplements has offset some of the negative impacts of COVID-19, and, when the cough and cold season returns, points to a bright future for the European OTC market.